Table 1 Baseline characteristics of participants according to the tertiles of the TyG index
Variables | Tertile 1 (n = 277) | Tertile 2 (n = 276) | Tertile 3 (n = 277) | p-value |
|---|---|---|---|---|
TyG index | 8.04 ± 0.26 | 8.57 ± 0.12 | 9.17 ± 0.33 | < 0.001 |
General conditions | ||||
 Age (years) | 63.57 ± 7.98 | 62.93 ± 7.88 | 61.88 ± 8.58 | 0.048 |
 Male, n (%) | 218 (78.7) | 206 (74.6) | 193 (69.7) | 0.051 |
 BMI (kg/m2) | 24.48 ± 3.41 | 26.00 ± 3.83 | 26.31 ± 3.51 | < 0.001 |
 LVEF (%) | 58.56 ± 10.30 | 59.01 ± 9.63 | 58.86 ± 10.56 | 0.866 |
 Prediabetes, n (%) | 19 (6.9) | 55 (19.9) | 124 (44.8) | < 0.001 |
 Previous MI, n (%) | 49 (17.7) | 53 (19.2) | 68 (24.5) | 0.110 |
 Previous stroke, n (%) | 33 (11.9) | 34 (12.3) | 43 (15.5) | 0.390 |
 Previous PCI, n (%) | 27 (9.7) | 29 (10.5) | 23 (8.3) | 0.669 |
 Left main disease, n (%) | 54 (19.5) | 61 (22.1) | 76 (27.4) | 0.077 |
 Multivessel disease, n (%) | 257 (92.8) | 254 (92.0) | 263 (94.9) | 0.365 |
Risk factors, n (%) | ||||
 Current smoking | 86 (31.0) | 71 (25.7) | 85 (30.7) | 0.306 |
 Current drinking | 73 (26.4) | 71 (25.7) | 80 (28.9) | 0.676 |
 FH-CAD | 51 (18.4) | 45 (16.3) | 60 (21.7) | 0.267 |
 Hypertension | 153 (55.2) | 157 (56.9) | 183 (66.1) | 0.020 |
 Hyperlipidemia | 66 (23.8) | 82 (29.7) | 99 (35.7) | 0.009 |
Surgical procedure | ||||
 Duration of surgery (min) | 270.00 (235.00–310.00) | 270.00 (230.00–313.75) | 270.00 (240.00–325.00) | 0.483 |
 OPCABG, n (%) | 250 (90.3) | 250 (90.6) | 239 (86.3) | 0.197 |
 Number of grafts | 3.53 ± 1.01 | 3.65 ± 1.04 | 3.66 ± 0.98 | 0.259 |
 Use of arterial grafts, n (%) | 264 (95.3) | 264 (95.7) | 266 (96.0) | 0.917 |
  Left internal mammary artery, n (%) | 248 (89.5) | 243 (88.0) | 249 (89.9) | 0.760 |
  Right internal mammary artery, n (%) | 25 (9.0) | 30 (10.9) | 26 (9.4) | 0.741 |
  Radial artery, n (%) | 10 (3.6) | 12 (4.3) | 11 (4.0) | 0.906 |
  Complete revascularization, n (%) | 260 (93.9) | 254 (92.0) | 259 (93.5) | 0.665 |
  Use of IABP, n (%) | 10 (3.6) | 12 (4.3) | 11 (4.0) | 0.906 |
Laboratory tests | ||||
 FPG (mmol/L) | 4.66 (4.33–5.07) | 5.02 (4.71–5.61) | 5.57 (4.98–6.01) | < 0.001 |
 TC (mmol/L) | 3.85 (3.20–4.50) | 4.01 (3.50–4.97) | 4.51 (3.83–5.14) | < 0.001 |
 TG (mmol/L) | 0.87 (0.70–1.01) | 1.30 (1.14–1.47) | 1.96 (1.61–2.46) | < 0.001 |
 LDL-C (mmol/L) | 2.20 (1.74–2.76) | 2.55 (2.01–3.12) | 2.69 (2.12–3.35) | < 0.001 |
 HDL-C (mmol/L) | 1.19 ± 0.25 | 1.12 ± 0.29 | 1.08 ± 0.23 | < 0.001 |
 eGFR (mL/min/1.73m2) | 91.35 ± 13.15 | 90.63 ± 13.45 | 90.70 ± 13.61 | 0.787 |
Cardiovascular medications, n (%) | ||||
 Antiplatelet drugs | 272 (98.2) | 268 (97.1) | 272 (98.2) | 0.595 |
 Statins | 227 (81.9) | 237 (85.9) | 226 (81.6) | 0.329 |
 ACEI/ARB | 102 (36.8) | 117 (42.4) | 121 (43.7) | 0.218 |
 Beta-blockers | 247 (89.2) | 254 (92.0) | 242 (87.4) | 0.196 |
 Diuretics | ||||
  Loop diuretics | 24 (8.7) | 27 (9.8) | 33 (11.9) | 0.436 |
  Thiazide diuretics | 40 (14.4) | 38 (13.8) | 48 (17.3) | 0.463 |
  Mineralocorticoid receptor antagonists | 46 (16.6) | 39 (14.1) | 50 (18.1) | 0.450 |
EuroSCORE II | 1.35 (0.97–2.34) | 1.35 (0.99–2.44) | 1.38 (0.95–2.10) | 0.613 |
MACE, n (%) | 39 (14.1) | 45 (16.3) | 80 (28.9) | < 0.001 |